Update in treatment of uveitic macular edema
Spyridon Koronis,1 Panagiotis Stavrakas,2 Miltiadis Balidis,1 Nikolaos Kozeis,1 Paris G Tranos1 1Ophthalmica Eye Institute, Thessaloniki, Greece; 2Department of Ophthalmology, Attikon University Hospital, Athens, Greece Abstract: Macular edema (ME) represents the most common cause for visual loss...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-02-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/update-in-treatment-of-uveitic-macular-edema-peer-reviewed-article-DDDT |
id |
doaj-43bf3d876bab46f3ad0d202f6e51618a |
---|---|
record_format |
Article |
spelling |
doaj-43bf3d876bab46f3ad0d202f6e51618a2020-11-24T21:13:44ZengDove Medical PressDrug Design, Development and Therapy1177-88812019-02-01Volume 1366768044146Update in treatment of uveitic macular edemaKoronis SStavrakas PBalidis MKozeis NTranos PGSpyridon Koronis,1 Panagiotis Stavrakas,2 Miltiadis Balidis,1 Nikolaos Kozeis,1 Paris G Tranos1 1Ophthalmica Eye Institute, Thessaloniki, Greece; 2Department of Ophthalmology, Attikon University Hospital, Athens, Greece Abstract: Macular edema (ME) represents the most common cause for visual loss among uveitis patients. The management of uveitic macular edema (UME) may be challenging, due to its often recalcitrant nature. Corticosteroids remain the mainstay of treatment, through their capability of effectively controlling inflammation and the associated ME. Topical steroids may be effective in milder cases of UME, particularly in edema associated with anterior uveitis. Posterior sub-Tenon and orbital floor steroids, as well as intravitreal steroids often induce rapid regression of UME, although this may be followed by recurrence of the pathology. Intravitreal corticosteroid implants provide sustained release of steroids facilitating regression of ME with less frequent injections. Topical nonsteroidal anti-inflammatory drugs may provide a safe alternative or adjuvant therapy to topical steroids in mild UME, predominantly in cases with underlying anterior uveitis. Immunomodulators including methotrexate, mycophenolate mofetil, tacrolimus, azathioprine, and cyclosporine, as well as biologic agents, notably the anti-tumor necrosis factor-α monoclonal antibodies adalimumab and infliximab, may accomplish the control of inflammation and associated ME in refractory cases, or enable the tapering of steroids. Newer biotherapies have demonstrated promising outcomes and may be considered in persisting cases of UME. Keywords: uveitis, macular edema, treatment, corticosteroids, dexamethasone implant, NSAIDs, anti-TNFα, interferonshttps://www.dovepress.com/update-in-treatment-of-uveitic-macular-edema-peer-reviewed-article-DDDTuveitisuveitic macular edematreatment. |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Koronis S Stavrakas P Balidis M Kozeis N Tranos PG |
spellingShingle |
Koronis S Stavrakas P Balidis M Kozeis N Tranos PG Update in treatment of uveitic macular edema Drug Design, Development and Therapy uveitis uveitic macular edema treatment. |
author_facet |
Koronis S Stavrakas P Balidis M Kozeis N Tranos PG |
author_sort |
Koronis S |
title |
Update in treatment of uveitic macular edema |
title_short |
Update in treatment of uveitic macular edema |
title_full |
Update in treatment of uveitic macular edema |
title_fullStr |
Update in treatment of uveitic macular edema |
title_full_unstemmed |
Update in treatment of uveitic macular edema |
title_sort |
update in treatment of uveitic macular edema |
publisher |
Dove Medical Press |
series |
Drug Design, Development and Therapy |
issn |
1177-8881 |
publishDate |
2019-02-01 |
description |
Spyridon Koronis,1 Panagiotis Stavrakas,2 Miltiadis Balidis,1 Nikolaos Kozeis,1 Paris G Tranos1 1Ophthalmica Eye Institute, Thessaloniki, Greece; 2Department of Ophthalmology, Attikon University Hospital, Athens, Greece Abstract: Macular edema (ME) represents the most common cause for visual loss among uveitis patients. The management of uveitic macular edema (UME) may be challenging, due to its often recalcitrant nature. Corticosteroids remain the mainstay of treatment, through their capability of effectively controlling inflammation and the associated ME. Topical steroids may be effective in milder cases of UME, particularly in edema associated with anterior uveitis. Posterior sub-Tenon and orbital floor steroids, as well as intravitreal steroids often induce rapid regression of UME, although this may be followed by recurrence of the pathology. Intravitreal corticosteroid implants provide sustained release of steroids facilitating regression of ME with less frequent injections. Topical nonsteroidal anti-inflammatory drugs may provide a safe alternative or adjuvant therapy to topical steroids in mild UME, predominantly in cases with underlying anterior uveitis. Immunomodulators including methotrexate, mycophenolate mofetil, tacrolimus, azathioprine, and cyclosporine, as well as biologic agents, notably the anti-tumor necrosis factor-α monoclonal antibodies adalimumab and infliximab, may accomplish the control of inflammation and associated ME in refractory cases, or enable the tapering of steroids. Newer biotherapies have demonstrated promising outcomes and may be considered in persisting cases of UME. Keywords: uveitis, macular edema, treatment, corticosteroids, dexamethasone implant, NSAIDs, anti-TNFα, interferons |
topic |
uveitis uveitic macular edema treatment. |
url |
https://www.dovepress.com/update-in-treatment-of-uveitic-macular-edema-peer-reviewed-article-DDDT |
work_keys_str_mv |
AT koroniss updateintreatmentofuveiticmacularedema AT stavrakasp updateintreatmentofuveiticmacularedema AT balidism updateintreatmentofuveiticmacularedema AT kozeisn updateintreatmentofuveiticmacularedema AT tranospg updateintreatmentofuveiticmacularedema |
_version_ |
1716748395965579264 |